One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
Cardiol Therapeutics Inc.
CRDL · NCM · Healthcare · Drug Manufacturers - Specialty & Generic
Current price
$1.12
52-week range
$0.88 - $2.34
Market cap
$136.09M
Balance sheet
Healthy
-47.24x Concerning
Net cash $18.53M. Interest coverage shows how many times profit covers the interest bill.
What stands out
0 Rewards
2 Risks
0 rewards · 2 risks
- Risk Return on equity was -190.2% last year — the company lost money on shareholders' equity.
- Risk Insider ownership is only 2.3% (peer median: 38.8%).
What this company does
Cardiol Therapeutics Inc.
Cardiol Therapeutics is developing new medicines, like CardiolRx and CRD-38, to help people with heart problems related to inflammation and scarring. Their main focus is on testing these drugs in clinical trials, which are like scientific experiments to see if they work and are safe for patients. The success of these trials is crucial for the company's future as it determines if their potential new treatments can reach the market and help patients.
Price history
How the share price has moved
—
Loading price history…
Is it cheap or expensive?
Fair value — vs current price $1.12
We couldn't calculate a fair value right now.
Is it drowning in debt?
Healthy
Net cash $18.5M - more cash than debt. Interest coverage -47.2x.
Net debt
$-18.53M
Interest coverage
-47.24x
Cardiol Therapeutics Inc.'s profit covers its interest bill about 0.0 times over. which is weaker than most peers shown here and 3 peers sit below 1x, which is the danger zone where profit does not fully cover the interest bill.
Healthy
Worse cushion
Baseline
Better cushion
CRDL
BASELINE
Cardiol Therapeutics Inc.
Total debt $76.35K Interest coverage -47.24x This is the baseline the peer rows are being compared against.
Total debt $25.54M Interest coverage -2.21x Neither company has much profit cushion over interest right now.
Total debt $66.95M Interest coverage 36.18x This peer still has a real interest-payment cushion, while CRDL does not.
Total debt $156.38M Interest coverage -0.54x Neither company has much profit cushion over interest right now.
Total debt $0.00 Interest coverage -5,468.00x Neither company has much profit cushion over interest right now.
What you should know
The case for and against CRDL
0 Rewards
2 Risks
Rewards
Risks
-
Return on equity was -190.2% last year — the company lost money on shareholders' equity.
-
Insider ownership is only 2.3% (peer median: 38.8%).
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
-4.81x
P/B
7.60x
P/S
—
EV/EBITDA
-2.92x
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
ROE
-190.2%
ROA
-90.9%
Health
Liquidity and balance-sheet strength
Debt / equity
0.00x
Current ratio
5.55x
Quick ratio
5.01x
Total debt
$76.35K
Total cash
$18.61M
Growth
How the business has been compounding
Revenue TTM
$0.00
Revenue 5Y CAGR
—
EPS TTM
-0.25
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-17.02M
Free CF TTM
$-17.04M
FCF margin
—
Dividend
Shareholder payout
Yield
0.0%
Payout ratio
—
Last ex-div date
—